Advances in multiple myeloma therapy are suppressing the dreaded expectations of a daunting disease. How are the latest treatment modalities presenting new avenues for cancer therapy? How can we work to improve our awareness of the changing face of multiple myeloma? Dr. James Berenson, founding president and chief executive officer of the Institute for Myeloma and Bone Cancer Research in West Hollywood, Calif., explores developments in multiple myeloma therapy that are improving prognoses for our patients. Dr. Mark Nolan Hill hosts.
ReachMD
Be part of the knowledge.™Register
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?
Improving the Prognoses of Multiple Myeloma
Share this program on:
Choose a format
Media formats available:
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Details
Presenters
Comments
Presenters
Recommended
Details
Presenters
Comments
Recommended
Overview
Advances in multiple myeloma therapy are suppressing the dreaded expectations of a daunting disease. How are the latest treatment modalities presenting new avenues for cancer therapy? How can we work to improve our awareness of the changing face of multiple myeloma? Dr. James Berenson, founding president and chief executive officer of the Institute for Myeloma and Bone Cancer Research in West Hollywood, Calif., explores developments in multiple myeloma therapy that are improving prognoses for our patients. Dr. Mark Nolan Hill hosts.
Presenters
Facebook Comments